Higher Basidiomycetes mushrooms have been used in folk medicine throughout the world since ancient times. For millennia, mushrooms have been valued by humankind as edible and medicinal resources. Traditional use of mushrooms as medicines has been long established among diff erent ethnic groups. In the Far East countries, especially in China, Japan, and Korea, mushrooms have long been revered for their curative attributes.
Paramount among these is Ganoderma lucidum (W. Curt.: Fr.) Lloyd (Ling zhi in Chinese; Reishi, Mannentake, or Sachitake in Japanise; and Youngzhi in Korea). It is valued for both its medicinal and spiritual properties. For centures, this mushroom has been regarded in the Orient as an eff ective medicinal source. It is also considered a symbol of happy augury and good fortune, good health, longevity, and even life with the immortals. Th e number of mushrooms on Earth is estimated at 140,000, yet perhaps only 10% (approximately 14,000 named species) are known. Edible higher Basidiomycetes are being evaluated for their nutritional value and acceptability, as well as their pharmacological properties. Th ey make up a vast and yet largely untapped source of powerful new pharmaceutical products. In particular, and most importantly for modern medicine, they present an unlimited source of polysaccharides with anticancer and immunostimulating properties. Many, if not all, Basidiomycetes mushrooms contain biologically active polysaccharides in their fruit bodies, cultured mycelia, and culture broth.
Th e data about mushroom polysaccharides are summarized for 651 species and seven intraspecifi c taxa from 182 genera of higher Hetero-and Homobasidiomycetes. Th ese polysaccharides are of diff erent chemical composition; the main ones comprise the group of β-glucans. β-(1→3) linkages in the main chain of the glucan and further β-(1→ 6) branch points are needed for their antitumor action. Numerous bioactive polysaccharides or polysaccharide-protein complexes from medicinal mushrooms are described that appear to enhance innate and cell-mediated immune responses and exhibit antitumor activities in animals and humans.
Stimulation of host immune defense systems by bioactive polymers from medicinal mush- In the second half of the 20t century, mushroom-producing technologies grew enormously. Mushrooms represent a valuable source of bioactive agents with potent and unique medicinal properties.
Some of recently isolated and identifi ed substances of Higher Basidiomycetes mushroom origin express promising antitumor, immune modulating, antioxidant, cardiovascular, antihypercholesterolemia, antiviral, antibacterial, antiparasitic, hepatoprotective, and antidiabetic eff ects.
Many of them are not strictly pharmaceutical products (real medicines) but represent a novel class of dietary supplements (DSs) or "mushroom nutriceuticals." Th e agents derived from medicinal mushroom fruit bodies, cultured mycelium, and/or culture fi ltrates exert a wide range of benefi cial biological eff ects when tested in vitro or using animal models. Recent years have seen a surge of commercial interest in medicinal mushroom DSs, the common market value of which is approximately $13 billion US dollars.
Th e safety advantages of using mushroom-based DSs, as opposed to herbal preparations are the following. (1) Th e overwhelming majority of mushrooms used for production of DSs are cultivated commercially (and not gathered in the wild); this provides a very good chance of proper identifi cation, and pure and unadulterated products. In many cases it also means genetic uniformity. (2) Mushrooms are easily propagated vegetatively and thus keep to one clone. Th e mycelium can be stored for a long time, and the genetic and biochemical consistency may be checked after considerable time. (3) Th e main advantage, in our opinion, is that many mushrooms are capable of growing in the form of mycelia biomass in submerged cultures.
